Nephro Care India
- P/E
- 64.46
Key Fundamentals
SMEHealthcare ServicesHealthcarePrice-based figures as of · TTM
- ROCE
- 7.90%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹1.20
- Book Value
- ₹34.49
- Market Cap
- —
- P/E (TTM)
- 64.46
- P/B
- 2.24
- ROE
- 5.07%
- Dividend Yield
- 0.00%
- EBITDA
- ₹9.90 Cr
- 52W High
- ₹156.35
- 52W Low
- ₹50.05
- Day Range
- ₹76.20 – ₹79.50
- Volume
- 18,000
Peer Comparison
Healthcare › Healthcare Services › Hospitals › Hospital
| ₹8,599.50 | 59.18 | ₹1,22,850 Cr | 13.04 | 0.24% | 21.20% | 17.40% | ₹26,430 Cr | ₹2,171 Cr | |
| ₹927.15 | 61.89 | ₹89,301 Cr | 7.96 | 0.22% | 14.70% | 14.70% | ₹8,712 Cr | ₹1,457 Cr | |
| ₹667.20 | 88.96 | ₹86,479 Cr | 5.34 | 0.00% | 6.64% | 8.30% | ₹11,400 Cr | ₹906 Cr | |
| ₹719.55 | 117.00 | ₹59,927 Cr | 14.91 | 0.44% | 11.30% | 11.60% | ₹4,876 Cr | ₹363 Cr | |
| ₹790.65 | 56.96 | ₹59,706 Cr | 6.03 | 0.13% | 11.20% | 13.40% | ₹9,506 Cr | ₹1,070 Cr | |
| ₹1,931.50 | 48.36 | ₹39,090 Cr | 7.89 | 0.24% | 20.50% | 15.50% | ₹9,072 Cr | ₹816 Cr | |
| ₹1,402.00 | 67.76 | ₹37,618 Cr | 9.52 | 0.04% | 15.20% | 17.40% | ₹4,683 Cr | ₹552 Cr | |
| Nephro Care (this company) | ₹77.35 | 64.46 | ₹131 Cr | 2.24 | 0.00% | 5.07% | 7.90% | ₹74 Cr | ₹2 Cr |
| Median 8 companies | ₹858.90 | 63.18 | ₹59,817 Cr | 7.93 | 0.18% | 13.00% | 14.05% | ₹8,892 Cr | ₹861 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 70
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 27
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 43
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 39
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 9.53% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 3 | 4 |
| Oscillators | Bullish | 2 | 3 | 4 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 35.51
- Neutral
- MACD (12,26,9)
- −2.49
- Bearish
- SMA (50)
- 89.12
- Bearish
- SMA (200)
- 80.82
- Bearish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +117.58% |
|---|---|
| 3Y | +73.16% |
| 1Y | +92.79% |
Net profit
| 5Y | +106.38% |
|---|---|
| 3Y | +12.45% |
| 1Y | −7.42% |
Operating cash flow
| 5Y | +57.23% |
|---|---|
| 3Y | −18.75% |
| 1Y | −69.48% |
Operating margin· change in pp
| 5Y | +1.14 pp |
|---|---|
| 3Y | −10.69 pp |
| 1Y | −3.37 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2020 | ₹0.54 Cr |
|---|---|
| Mar 2021 | ₹1.82 Cr |
| Mar 2022 | ₹3.42 Cr |
| Mar 2023 | ₹17.09 Cr |
| Mar 2024 | ₹27.23 Cr |
| Mar 2025 | ₹46.03 Cr |
| Mar 2026 | ₹88.74 Cr |
Net profit by year
| Mar 2020 | −₹0.01 Cr |
|---|---|
| Mar 2021 | ₹0.09 Cr |
| Mar 2022 | −₹0.01 Cr |
| Mar 2023 | ₹2.37 Cr |
| Mar 2024 | ₹4.41 Cr |
| Mar 2025 | ₹3.64 Cr |
| Mar 2026 | ₹3.37 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 17.33 | 22.66 | 26.75 | 29.19 |
| Expenses | 16.73 | 20.75 | 24.73 | 25.57 |
| Operating Profit | 0.6 | 1.91 | 2.02 | 3.62 |
| OPM % | 3.46% | 8.43% | 7.55% | 12.4% |
| Other Income | 0.05 | 0.08 | 0.83 | 0.22 |
| Interest | 0.14 | 0.03 | −0.01 | 0.03 |
| Depreciation | 1.16 | 1.4 | 1.56 | 1.19 |
| PBT | −0.65 | 0.56 | 1.3 | 2.62 |
| Tax % | 0% | 25% | 23.08% | 38.17% |
| Net Profit | −0.65 | 0.42 | 1 | 1.61 |
| EPS (₹) | −0.39 | 0.25 | 0.61 | 0.98 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 0.54 | 1.82 | 3.42 | 17.09 | 27.23 | 46.03 | 88.74 |
| Expenses | 0.52 | 1.67 | 3.28 | 13.66 | 20.76 | 40.16 | 80.42 |
| Operating Profit | 0.02 | 0.15 | 0.14 | 3.43 | 6.47 | 5.87 | 8.32 |
| OPM % | 3.7% | 8.24% | 4.09% | 20.07% | 23.76% | 12.75% | 9.38% |
| Other Income | 0.01 | 0.01 | −0.01 | 0 | 0.28 | 1.53 | 1.55 |
| Interest | 0.04 | 0.03 | 0.02 | 0.07 | 0.09 | 0.11 | 0.16 |
| Depreciation | 0 | 0.01 | 0.11 | 0.78 | 0.53 | 2.46 | 5.07 |
| PBT | −0.01 | 0.12 | 0 | 2.58 | 6.13 | 4.83 | 4.64 |
| Tax % | 0% | 25% | — | 7.75% | 28.06% | 24.64% | 27.37% |
| Net Profit | −0.01 | 0.09 | −0.01 | 2.37 | 4.41 | 3.64 | 3.37 |
| EPS (₹) | −10 | 90 | −0.2 | 47.4 | 3.71 | 2.21 | 2.04 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.5 | 0.5 | 11.9 | 16.49 | 16.49 |
| Reserves | 0.07 | 0.01 | 0 | 2.03 | 3.12 | 37 | 40.37 |
| Borrowings | 0.4 | 0.69 | 2.54 | 2.48 | 0 | 0 | 0 |
| Other Liabilities | 0.3 | 0.42 | 1.6 | 3.25 | 5.94 | 14.79 | 15.81 |
| Total Liabilities | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |
| Fixed Assets | 0.45 | 0.06 | 1.39 | 3.01 | 4.74 | 31.48 | 34.01 |
| CWIP | 0 | 0.45 | 1.9 | 0 | 0.86 | 0.61 | 0.53 |
| Investments | 0.24 | 0 | 0 | 2 | 6.51 | 18.58 | 11.81 |
| Other Assets | 0.09 | 0.62 | 1.35 | 3.25 | 8.85 | 17.61 | 26.32 |
| Total Assets | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | — | 0.23 | 0.62 | 4.12 | 0.91 | 7.24 | 2.21 |
| Investing | — | −0.06 | −2.81 | −2.33 | −7.54 | −39.83 | −0.48 |
| Financing | — | 0.28 | 2.32 | −0.08 | 5.6 | 35.96 | 0 |
| Net Cash Flow | — | 0.44 | 0.13 | 1.71 | −1.03 | 3.37 | 1.73 |
| Free Cash Flow | — | 0.16 | −2.28 | 3.62 | −2.38 | −22.56 | −5.59 |
| CFO/OP | — | 133 | 493 | 121 | 50 | 141 | 48 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 20.28 | 0.85 | 2.01 | 25.61 | 24.84 |
| Inventory Days | — | 8.83 | 41.93 | 35.25 | 14.07 | 34.38 | 31.68 |
| Days Payable | — | 94.19 | 113 | 69.03 | 75.17 | 107 | 92.84 |
| Cash Conversion Cycle | 0 | −85.36 | −51.24 | −32.93 | −59.09 | −47.33 | −36.31 |
| Working Capital Days | −169 | −88.24 | −125 | −56.81 | −36.86 | −51.15 | −4.07 |
| ROCE % | — | 25.21% | 1.6% | 65.84% | 60.41% | 11.27% | 7.9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nephro Care insights
55 extracted metrics across FY20–FY27.
Documents
- Concall · Aug 2025PPT
- 5 Oct 2026
- 28 Sep 2026
- 25 Sep 2026
- 15 Sep 2026
Frequently Asked Questions about Nephro Care India
What does Nephro Care India Ltd do?
Where is Nephro Care India Ltd (NEPHROCARE) listed?
Which sector does Nephro Care India Ltd belong to?
What is the PE ratio of Nephro Care India Ltd?
What is the 52-week high and low of Nephro Care India Ltd?
What is the Return on Equity (ROE) of Nephro Care India Ltd?
Company Information
Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes in the treatment of kidney- related diseases
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEPHROCARE.md for Nephro Care India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.